Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144351 | 0.82 | ERN1 (0.57) | ERN1ALDH1A1TSHRCYP2A6PTPN1 | |
| SCHEMBL31401340 | 0.82 | ERN1 (0.57) | ERN1ALDH1A1TSHRCYP2A6PTPN1 | |
| SCHEMBL3040456 | 0.78 | ERN1 (0.64) | ERN1ALDH1A1CYP2A6PTPN1PTGDR2 | |
| SCHEMBL15978830 | 0.78 | MAOB (0.41) | ALDH1A1PTGDR2TYR | |
| SCHEMBL31672723 | 0.77 | CASP3 (0.35) | ERN1ALDH1A1HCAR1CYP1A2CYP2D6 | |
| SCHEMBL27346950 | 0.77 | MPO (0.38) | ERN1ALDH1A1HCAR1CYP1A2CYP2D6 | |
| SCHEMBL17449355 | 0.77 | ALDH1A1 (0.35) | ERN1ALDH1A1TSHRHCAR1SMN1; SMN2 | |
| SCHEMBL3859028 | 0.77 | CASP3 (0.35) | ERN1ALDH1A1HCAR1CYP1A2CYP2D6 | |
| SCHEMBL28805080 | 0.77 | HCAR1 (0.35) | ERN1ALDH1A1TSHRHCAR1 | |
| SCHEMBL1162125 | 0.76 | ERN1 (0.56) | ERN1ALDH1A1CYP2A6PTPN1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327243-B | Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof | 天津师范大学 | 2024-04-30 | — | — | CN | claimed |
| CN-117327243-A | Olefin-linked two-dimensional covalent organic framework, and preparation method and application thereof | 天津师范大学 | 2024-01-02 | — | — | CN | claimed |
| CN-116947754-A | Antitumor compound, antitumor drug, preparation method and application | 北京中医药大学 | 2023-10-27 | — | — | CN | claimed |
| CN-113387982-B | Methyl-modified cage-type phosphorus ligand, preparation method and application thereof | 东莞理工学院 | 2022-04-19 | — | — | CN | claimed |
| CN-113387982-A | Methyl-modified cage-type phosphorus ligand, preparation method and application thereof | 东莞理工学院 | 2021-09-14 | — | — | CN | claimed |
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| EP-4673150-A2 | COMPOSITIONS AND METHODS FOR TREATING MALT1 ASSOCIATED DISEASES | Rarefied Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-1131322-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000024741-A2 | DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0104432-A2 | Herbicide and plant growth regulator comprising alpha-beta-unsaturated compound | TEIJIN LIMITED (JP) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | ERN1 3600/4885ALDH1A1 205/4885TSHR 1609/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | ERN1 2787/4885ALDH1A1 2463/4885TSHR 303/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | ERN1 3729/4885ALDH1A1 266/4885TSHR 3000/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | ERN1 1646/4885ALDH1A1 296/4885TSHR 1900/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | ERN1 2884/4885ALDH1A1 747/4885TSHR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.